These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27021607)

  • 61. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
    Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
    Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Belimumab. No tangible efficacy but a risk of immunosuppression.
    Prescrire Int; 2013 Jun; 22(139):149. PubMed ID: 23866349
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus.
    Nakai T; Fukui S; Kidoguchi G; Ikeda Y; Kitada A; Nomura A; Tamaki H; Kishimoto M; Okada M
    Clin Rheumatol; 2022 Dec; 41(12):3735-3745. PubMed ID: 35939162
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The safety of belimumab for the treatment of systemic lupus erythematosus.
    Wise LM; Stohl W
    Expert Opin Drug Saf; 2019 Dec; 18(12):1133-1144. PubMed ID: 31657965
    [No Abstract]   [Full Text] [Related]  

  • 65. Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta-Analysis.
    Kneeland R; Montes D; Endo J; Shields B; Bartels CM; Garg S
    Arthritis Care Res (Hoboken); 2023 Aug; 75(8):1838-1848. PubMed ID: 36358025
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus.
    Bruce IN; Golam S; Steenkamp J; Wang P; Worthington E; Desta B; Psachoulia K; Erhardt W; Tummala R
    J Comp Eff Res; 2022 Jul; 11(10):765-777. PubMed ID: 35546484
    [No Abstract]   [Full Text] [Related]  

  • 68. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.
    Danve A; Perry L; Deodhar A
    Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
    Sciascia S; Radin M; Yazdany J; Levy RA; Roccatello D; Dall'Era M; Cuadrado MJ
    Autoimmun Rev; 2017 Mar; 16(3):287-293. PubMed ID: 28147262
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Belimumab in the management of systemic lupus erythematosus - an update.
    Tesar V; Hruskova Z
    Expert Opin Biol Ther; 2017 Jul; 17(7):901-908. PubMed ID: 28460578
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Post-marketing experiences with belimumab in the treatment of SLE patients.
    Askanase AD; Yazdany J; Molta CT
    Rheum Dis Clin North Am; 2014 Aug; 40(3):507-17, viii. PubMed ID: 25034159
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic review.
    Peterknecht E; Keasey MP; Beresford MW
    Lupus; 2018 Nov; 27(13):2135-2145. PubMed ID: 30336753
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
    Deng WP
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1069-1074. PubMed ID: 34719425
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Belimumab for the management of systemic lupus erythematosus.
    Lutalo PM; D'Cruz DP
    Expert Opin Biol Ther; 2012 Jul; 12(7):957-63. PubMed ID: 22646798
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.
    Sheikh SZ; Hammer AE; Fox NL; Groark J; Struemper H; Roth D; Gordon D
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):914-922. PubMed ID: 27668697
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Recommendation for use of belimumab for systemic lupus erythematosus].
    Fischer-Betz R; Schneider M;
    Z Rheumatol; 2013 Jun; 72(5):462-7. PubMed ID: 23695423
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
    Oon S; Huq M; Golder V; Ong PX; Morand EF; Nikpour M
    Ann Rheum Dis; 2019 May; 78(5):629-633. PubMed ID: 30679152
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Belimumab for systemic lupus erythematosus: a practice-based view.
    Parodis I; Axelsson M; Gunnarsson I
    Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.